Rare Disease Report

Summary of the Phase 3 Data for Amifampridine Phosphate to Treat LEMS

APRIL 25, 2015


In this exclusive interview with Rare Disease Report, Shin Oh, MD, of University of Alabama at Birmingham summarizes the clinical data available supporting the use of amifampridine phosphate (Firdapse) to treat patients with Lambert-Eaton myasthenic syndrome (LEMS).

LEMS is a rare autoimmune disease that can be severely disabling, with the primary symptoms being severe muscle weakness.

For more information, visit http://catalystpharma.com/

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
$related$
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.